OFOlufemi Fasanmade

Olufemi Fasanmade

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Olufemi Fasanmade has a total of 161 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Periodontal Therapy–Related Changes in Clinical Parameters, Active‐Matrix Metalloproteinase‐8 and C‐Reactive Protein in Prediabetes and Diabetes

    by Kehinde Adesola Umeizudike, Olayiwola Ibrahim Olaoye, Ayodele Charles Ogundana, Ismo T. Räisänen, Solomon Olusegun Nwhator, Babatunde Yusuf Alli, Patricia Omowunmi Ayanbadejo, Olufemi Adetola Fasanmade, Timo Sorsa

    Objectives: This study investigated the effect of nonsurgical periodontal therapy (NSPT) on periodontal clinical parameters, active‐matrix metalloproteinase‐8 (aMMP‐8), high sensitivity C‐reactive protein (hsCRP), and glycated hemoglobin (HbA1c), and their relationships in diabetes and prediabetes patients with periodontitis. Materials and Methods: In this prospective single‐arm, interventional (before‐and‐after) study, 77 Nigerian periodontitis patients with diabetes ( n = 45) and prediabetes ( n = 32) received NSPT. Clinical parameters [periodontal inflamed surface area (PISA), Plaque Index (PLI), Gingival Index (GI)], mouthrinse aMMP‐8, serum hsCRP, and HbA1c were measured at baseline and 3 months posttreatment. Analyses included paired t ‐tests, Pearson correlation, and linear mixed effect models ( p < 0.05). Results: Diabetes and prediabetes patients showed improvements in PISA, PLI, GI, aMMP‐8, HbA1c ( p < 0.001), and hsCRP ( p = 0.001) 3 months post‐NSPT. Diabetes patients maintained improvements, but hsCRP and HbA1c were insignificant in prediabetes. Diabetes participants had greater HbA1c reduction (−0.78%), while prediabetes participants had larger aMMP‐8 decrease (−20.91 ng/mL). Obesity reduced aMMP‐8 and PLI responses, with no sex effect. Several variables showed significant correlations. Conclusion: NSPT reduces systemic inflammation and improves glycemic control, particularly in diabetes. HbA1c responds best in diabetes, aMMP‐8 in prediabetes. Mouthrinse aMMP‐8 PoC test enables real‐time periodontal monitoring and supports diabetes risk screening in dental and medical care. Trial Registration: The registration number: PACTR202608587329540; Trial registry: Pan African Clinical Trials Registry (PACTR)

  • Open Access

    Analytical performance of four HbA1c point-of-care devices: a cross-sectional evaluation in low- and middle-income countries

    by Priyanka Singh, Erna Lenters-Westra, Kimcheng Choun, Olufemi Fasanmade, Berra Erkosar, Mikaela Watson, Cathy Haldane, Beatrice Vetter

    Objectives Glycated haemoglobin A1c (HbA1c) measurement is essential for managing diabetes, yet limited data exist on the performance of point-of-care (POC) HbA1c devices in low- and middle-income countries (LMICs). This study evaluated the analytical performance and usability of HbA1c devices in different LMIC settings. Design and setting This prospective, cross-sectional multicentre study evaluated the accuracy and usability of four POC devices (i-SENS A1Care, HemoCue HbA1c 501 System, Abbott Afinion 2 and Siemens DCA Vantage) against a laboratory-based HbA1c method at two hospitals in Nigeria and Cambodia. Participants Adults with or without diabetes and haemoglobin ≥8 g/dL were enrolled. Primary and secondary outcome measures The primary objective was to evaluate HbA1c POC device accuracy versus laboratory reference testing; secondary objectives evaluated device usability and technical characteristics when used by trained professionals. Intervention Capillary and venous blood samples were tested on all devices using two cartridge lots followed by reference testing. Usability was assessed via operator questionnaires. Accuracy was evaluated using regression slopes, intercept, absolute bias at 30, 48 and 75 mmol/mol, and Bland-Altman analysis, including capillary-venous concordance. Results A total of 248 participants completed all study procedures (n=125 in Cambodia, n=123 in Nigeria). Siemens DCA Vantage and Abbott Afinion 2 showed strong agreement with the reference method, with no clinically significant differences and narrow limits of agreement. In contrast, i-SENS A1Care and HemoCue HbA1c 501 System displayed greater bias, especially at elevated HbA1c levels. Most results fell within limits of agreement, though high-HbA1c outliers were more common with the A1Care and HbA1c 501 System devices. Usability feedback was positive overall, when devices were rated across various dimensions, such as clarity of instructions, safety and labelling, although limited user sample size constrains the generalisability of these findings. Conclusions Siemens DCA Vantage and Abbott Afinion 2 demonstrated reliable accuracy and usability. In contrast, i-SENS A1Care and HemoCue HbA1c 501 System require cautious interpretation at high HbA1c levels. Ongoing evaluation is critical to ensure the appropriate use of POC devices in diverse clinical settings. Trial registration number NCT06170515.

  • Open Access

    Effects of Non-Surgical Periodontal Therapy on Glycemic Control in Prediabetes and Diabetes Patients with Stage II–IV Periodontitis as Monitored by Active-Matrix Metalloproteinase-8 Levels

    by Kehinde Adesola Umeizudike, Solomon Olusegun Nwhator, Olayiwola Ibrahim Olaoye, Ayodele Charles Ogundana, Ismo T. Räisänen, Olufemi Adetola Fasanmade, Oladunni Ogundana, Obiefuna Ajie, Timo Sorsa

    Background/Objectives: Previous research indicates that non-surgical periodontal therapy (NSPT) improves glycemic control in individuals with prediabetes and diabetes who have periodontitis. Few studies have demonstrated its effects on mouthrinse active-matrix metalloproteinase-8 (aMMP-8) levels as it relates to glycemic control. We assessed the periodontal treatment response of stage II–IV periodontitis patients with prediabetes, diabetes, and normoglycemia, regarding glycated hemoglobin (HbA1c) and mouthrinse aMMP-8 levels using point-of-care kits (PoC). Materials and Methods: Eighty-eight adults (11 normoglycemic, 32 prediabetic, 45 with type 2 diabetes), aged 25–78, with stage II–IV periodontitis were included. Full-mouth clinical examinations were used to evaluate their periodontal parameters. HbA1c and mouthrinse aMMP-8 levels were assessed using PoC kits before and approximately three months after scaling and root planing. Results: There were positive treatment effects of non-surgical periodontal therapy on periodontal clinical parameters, aMMP-8 and HbA1c levels in the prediabetes and diabetes groups. The aMMP-8 reduction was significant (p < 0.001) in the prediabetes and prediabetes + diabetes groups, while HbA1c decreased significantly in the diabetes and prediabetes + diabetes (p < 0.001) groups. In contrast, a non-significant increase in mean aMMP-8 levels, HbA1c, and CAL was observed in normoglycemia (p > 0.05). Stage III + IV periodontitis showed significant treatment effects for aMMP-8 (p < 0.001) and HbA1c (p < 0.01) compared to stage II, regardless of glycemic status. Conclusions: Non-surgical periodontal therapy significantly improves periodontal health as well as HbA1c and aMMP-8 levels in people living with prediabetes and diabetes.


  • Growth hormone therapy in the management of short stature due to turner syndrome in Nigeria: a case report

    by Obiamaka Ede, Oluwarotimi Olopade, Ifedayo Odeniyi, Olufemi Fasanmade

    Introduction: Turner Syndrome (TS) is the most common chromosomal abnormality affecting phenotypic females. Short stature (SS) is one of the most consistent clinical features of TS, with consequent poor psychosocial outcomes. Management involves early diagnosis and administration of recombinant human growth hormone (rhGH). The cost of therapy however hampers treatment in resource-challenged regions. The objective of this presentation is to report the outcome and challenges of rhGH therapy in maximizing the height of patients with SS, in Nigeria, a resource-challenged setting. Case presentation: An 18-year-old schoolgirl presented to the endocrine clinic on account of short stature and failure to attain menarche. Childhood developmental milestones and academic performance were normal. Past medical and surgical history was unremarkable. She withdrew from high school as a result of stigmatization from her peers. General examination revealed scanty axillary and pubic hairs. Her height was 1.37m, Weight: 33 kg, BMI: 17.6 kg/m2, and arm span: 1.35m. Breast development was Tanner stage 1 with widely spaced nipples. Radiograph of left wrist showed bone age 11 years. Abdominopelvic ultrasound showed a hypoplastic uterus. Her blood tests showed elevated Follicle stimulating and Luteinizing hormone levels with reduced Serum oestradiol. Her karyotype was 45XO. A diagnosis of short stature secondary to Turner syndrome with hypergonadotropic hypogonadism was made. She was commenced on SC Growth hormone 1.62 mg four times weekly and also oestradiol therapy. Treatment was intermittently affected by financial constraints and poor supply chain due to Covid-19 pandemic. Her current height after 2 years of follow-up was 1.50m. She was then able to resume her academic pursuits. Conclusion: Early initiation of HGH in short stature improvesgrowth and allows appreciable progression to adult height, leading to enhanced quality of life. The high cost of rhGH (about £560 monthly) impairs effective management in resource-challenged regions like Nigeria where minimum wage is £58 monthly.

  • Open Access

    The sugar tax and obesity/overweight in Nigeria

    by Olufemi Adetola Fasanmade, Felicia Ohunene Anumah


  • Open Access

    Telemedicine Ready or Not? a cross-sectional assessment of telemedicine maturity of federally funded tertiary health institutions in Nigeria

    by Tolulope F. Olufunlayo, Oluwadamilola O. Ojo, Obianuju B. Ozoh, Osigwe P. Agabi, Chuks R. Opara, Funlola T. Taiwo, Olufemi A. Fasanmade, Njideka U. Okubadejo

    Background and Objective: Telemedicine (TM) has solidified its place as a means for continuity of healthcare services and a cost-effective approach for improving health equity as demonstrated during the COVID-19 pandemic. Preparedness of health systems for telemedicine is an indicator of the scalability of their services, especially during disasters. We aimed to assess the maturity and preparedness of federally funded tertiary health institutions (FFTHIs) in Nigeria, to deploy and integrate telemedicine Methods: We conducted a cross-sectional study of randomly selected FFTHIs in Nigeria using PAHO’s tool for assessing the maturity level of health institutions to implement telemedicine services. Descriptive statistics were used for overall maturity levels and non-parametric tests to compare scores for overall maturity and specific PAHO domains per region. The level of significance was set at p value <0.05. Results: Twenty-four of thirty randomly polled FFTHIs responded (response rate of 77.4%). Overall, the median TM maturity level was 2.0 (1.75) indicating beginner level. No significant inter-zonal difference in median overall maturity level (p=0.87). The median maturity levels for telemedicine readiness in specific domains were organizational readiness - 2.0 (2.0), processes 1.0 (1.0), digital environment 2.0 (3.0), human resources 2.0 (1.0), regulatory issues- 1.5 (1.0) and expertise 2.0 (2.0); mostly at beginner level, with no inter-zonal differences. Most participating institutions had no initiatives in place for domains of processes and regulatory issues. Conclusions: The current status of telemedicine maturity of FFTHIs in Nigeria behoves policy makers to advance the implementation of telemedicine across the country as part of national digital quality healthcare.

  • Open Access

    Type 2 diabetes complications and comorbidity in Sub-Saharan Africans

    by Kenneth Ekoru, Ayo Doumatey, Amy R. Bentley, Guanjie Chen, Jie Zhou, Daniel Shriner, Olufemi Fasanmade, Godfrey Okafor, Benjamin Eghan, Kofi Agyenim-Boateng, et al.


  • The chameleon - primary hyperparathyroidism: Still a diagnostic challenge

    by Oluwarotimi Olopade, Chinyere Udo, Ifedayo Odeniyi, Olufemi Fasanmade

    Introduction: Primary hyperparathyroidism is a common endocrine disorder. Symptoms at onset are often non-specific, thus the diagnosis tends to be overlooked. Objective: To highlight varying modes of presentation in primary hyperparathyroidism, the need for early recognition and treatment to prevent complications. Case Presentation: A 51-year old woman presented with complaints of back and lower limb pains of 7-year duration. She also has paresthesia in both feet and polyuria. She has history of compressive myelopathy and nephrolithiasis 3 and 6 years ago respectively. She had spine surgery and lithotripsy done in the Middle East, without pain resolution. Patient was eventually referred to the Endocrinologist following biopsy findings of extensive osteoclastic bone resorption. Elevated blood pressure was found on examination. Investigations–serum calcium 3.72 mmol/l (2.10–2.55), parathyroid hormone 1941 pg/ml (15–65), low Vitamin D 11 ng/ml, parathyroid nodule on Magnetic Resonance Imaging and nephrolithiasis on ultrasound scan. Dual Energy X-ray absorptiometry showed T-score of -12. Diagnosis of primary hyperparathyroidism complicated by severe osteoporosis and nephrolithiasis was made. She is presently on Tabs Alendronate, with clinical improvement, and being planned for parathyroidectomy. Discussion: Primary hyperparathyroidism is a disorder characterized by overproduction of parathyroid hormone resulting in abnormal calcium homeostasis. Parathyroid adenomas are the most common cause, as in this patient. Most patients are asymptomatic, others present with a myriad of symptoms. Nephrolithiasis, osteoporosis are common complications, identified as separate entities in this patient. Diagnosis is based on elevated serum parathyroid ±calcium. Definitive treatment is surgery. Without clear indications for surgery, regular monitoring for, and treatment of complications should be done. Conclusion: Holistic evaluation of patients’ clinical clues and symptoms facilitates early diagnosis. This limits complications, improving outcomes and quality of life in patients.

  • Frequency and predictors of sexual dysfunctions among male Nigerians with diabetes mellitus (A Preliminary report)

    by Oluwarotimi Olopade, Musa Kadijat, Nwaukwa Paulyn, Udo Chinyere, Bolanle Okunowo, Anyanwu Anthony, Ifedayo Odeniyi, Olufemi Fasanmade

    Introduction: Evaluation of sexual function is an integral part of general assessment of people with diabetes mellitus but this is rarely done. These comprises hypoactive sexual desire, erectile dysfunction (ED) and ejaculatory disorders. Presence of any of this will negatively impact on the sexual life of female partners. Objectives: To determine the frequency and determinants of sexual dysfunction among male patients with type 2 diabetes mellitus (T2DM). Methods: Cross sectional study carried out among consenting T2DM patients attendingdiabetes clinic using IIEF questionnaire. Anthropometric, clinical and biochemical parameters were obtained. Data was analyzed using SPSS version 20. Results: Sixty-five male consenting T2DM were analysed. The mean age of the participants was 58.6±12.3 years with duration for DM ranged from one to fifty years. 63.1% had both T2DM and hypertension while 33.8% had only DM. 44.6% were overweight and only 24.6% were on diuretics. Mean HbA1cand FBS values were 7.4±2.1% and 118±30 mg/dl respectively. The prevalence of hypoactive sexual desire is 78.4% while ED was 67.7% (38.6% had severe erectile dysfunction). 46.1% had ejaculatory disorders. Only 44.6% and 49.3% had intercourse satisfaction and overall sexual satisfaction respectively. There were significant association between advancing age, duration of DM and ED. Discussion: All the domains of sexual function were affected with hypoactive sexual desire being more frequent. Though predictors such as age, duration of DM and glycaemic controls affects ED, lack of sexual drive and ejaculatory problems could impact negatively on their female partners. This could lead to friction in relationships and eventually lack of social support needed by persons with DM. Conclusion: Focus on all aspect of sexual function in term of counselling and active treatment of affected individuals will probably improve quality of care for persons with DM.

  • Testicular Dysfunction is a Common Feature in Men with Type 2 Diabetes Mellitus in a Nigerian Tertiary Hospital

    by Onung Samuel Inih, Young Ekenechukwu Esther, Fasanmade Olufemi Adetola, Anyanwu Anthony Chinedu, Nwatu Chidinma Brenda, Ohwovoriole Augustine Efedaye

    Background: Hypogonadism in male patients with diabetes mellitus is associated with older age, obesity and poor glycaemic control. The patterns of sperm count, testicular volume, sperm motility and morphology have also been reported to be abnormal in these patients, though reports are conflicting. The objectives of this study were to assess gonadal function and sperm parameters in Nigerian males with diabetes mellitus. Methods: A study sample of 150 males consisting of 108 patients and 56 age-matched controls were recruited. The ADAM questionnaire was used to obtain a clinical score for hypogonadism. Laboratory parameters measured were fasting plasma glucose, serum LH, FSH, free testosterone, total cholesterol, LDL, HDL and triglyceride. Testicular volume was measured with a Prader orchidometer. Total sperm count, sperm morphology and motility were assessed. Results: Hypogonadism was present in 38.9% of males with diabetes compared to 3.6% in controls. The patients with diabetes had significantly lower sperm count, reduced sperm motility and increased abnormal forms than the controls (p<0.001, p=0.12, p<0.001). Only 8.5% of the patients did not demonstrate any abnormality in testicular function. Conclusion: Poor sperm function was more common than hypogonadism and was associated with poor glycaemic control (p<0.001). Likewise, hypogonadism was significantly associated with poor glycaemic control (p<0.001).